Hostname: page-component-74656f9884-2dmjx Total loading time: 0 Render date: 2026-11-06T22:21:34.516Z Has data issue: false hasContentIssue false

Mortality data reliability in an internal model

Published online by Cambridge University Press:  03 August 2020

Fabrice Balland
Affiliation:
GIE AXA, 21 Avenue Matignon, 75008Paris, France
Alexandre Boumezoued*
Affiliation:
Milliman, 14 Avenue de la Grande Armée, 75017Paris, France
Laurent Devineau
Affiliation:
Milliman, 14 Avenue de la Grande Armée, 75017Paris, France
Marine Habart
Affiliation:
GIE AXA, 21 Avenue Matignon, 75008Paris, France
Tom Popa
Affiliation:
GIE AXA, 21 Avenue Matignon, 75008Paris, France
*
*Corresponding author. Email: alexandre.boumezoued@milliman.com
Rights & Permissions [Opens in a new window]

Abstract

In this paper, we discuss the impact of some mortality data anomalies on an internal model capturing longevity risk in the Solvency 2 framework. In particular, we are concerned with abnormal cohort effects such as those for generations 1919 and 1920, for which the period tables provided by the Human Mortality Database show particularly low and high mortality rates, respectively. To provide corrected tables for the three countries of interest here (France, Italy and West Germany), we use the approach developed by Boumezoued for countries for which the method applies (France and Italy) and provide an extension of the method for West Germany as monthly fertility histories are not sufficient to cover the generations of interest. These mortality tables are crucial inputs to stochastic mortality models forecasting future scenarios, from which the extreme 0.5% longevity improvement can be extracted, allowing for the calculation of the solvency capital requirement. More precisely, to assess the impact of such anomalies in the Solvency II framework, we use a simplified internal model based on three usual stochastic models to project mortality rates in the future combined with a closure table methodology for older ages. Correcting this bias obviously improves the data quality of the mortality inputs, which is of paramount importance today, and slightly decreases the capital requirement. Overall, the longevity risk assessment remains stable, as well as the selection of the stochastic mortality model. As a collateral gain of this data quality improvement, the more regular estimated parameters allow for new insights and a refined assessment regarding longevity risk.

Information

Type
Paper
Copyright
© Institute and Faculty of Actuaries 2020
Figure 0

Figure 1. Abnormal cohort effects: example of the period table for France.

Figure 1

Figure 2. Number of births by months and correction indicator for France and Italy.

Figure 2

Figure 3. Number of births by months and correction indicator for West Germany.

Figure 3

Figure 4. Results of the linear regression.

Figure 4

Figure 5. Completion by regression of the correction indicator for West Germany.

Figure 5

Figure 6. Crude and adjusted mortality improvements for France and Italy.

Figure 6

Figure 7. From left to right: crude mortality improvements for West Germany, and the adjusted versions according to the BIC and R-squared criteria.

Figure 7

Figure 8. Convexity matrix for the raw and adjusted West Germany mortality table.

Figure 8

Figure 9. Historical period life expectancy at age 30, truncated at age 95, before and after HFD correction.

Figure 9

Figure 10. Comparative period force of mortality before and after HFD adjustment, France – Women population.

Figure 10

Figure 11. Period-based death functions, before (left) and after (right) HFD correction.

Figure 11

Figure 12. The mortality table adjustment process within the internal model workflow.

Figure 12

Figure 13. Lee–Carter model (M1) components fitting.

Figure 13

Figure 14. Age–period–cohort model (M3) components fitting.

Figure 14

Figure 15. Plat model components fitting.

Figure 15

Figure 16. Period and cohort life expectancy as of 2015 for French females, M1 model.

Figure 16

Figure 17. Period and cohort life expectancy as of 2015 for French females, M3 model.

Figure 17

Figure 18. BIC criteria for model calibration.

Figure 18

Figure 19. Baseline and longevity trend SCR future mortality for French females born in 1955.

Figure 19

Figure 20. Longevity SCR impact on cohort life expectancy in 2015 for French females born between 1925 and 1975.

Figure 20

Figure 21. Impact on longevity trend SCR.

Figure 21

Figure 22. Impact on life SCR.

Figure 22

Figure 23. Evolution of cohort life expectancy gap between baseline and longevity SCR trend between 2015 and 2016.